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Abstract
We have previously demonstrated hippocampal hyperglutamatergic signaling oc-
curs prior to plaque accumulation in AβPP/PS1 mice. Here, we evaluate 2-Amino-
6-(trifluoromethoxy) benzothiazole (riluzole) as an early intervention strategy for 
Alzheimer's disease (AD), aimed at restoring glutamate neurotransmission prior to 
substantial Beta amyloid (Aβ) plaque accumulation and cognitive decline. Male AβPP/
PS1 mice, a model of progressive cerebral amyloidosis, were treated with riluzole 
from 2–6 months of age. Morris water maze, in vivo electrochemistry, and immu-
nofluorescence were performed to assess cognition, glutamatergic neurotransmis-
sion, and pathology, respectively, at 12 months. Four months of prodromal riluzole 
treatment in AβPP/PS1 mice resulted in long-lasting procognitive effects and attenu-
ated glutamatergic tone that was observed six months after discontinuing riluzole 
treatment. Riluzole-treated AβPP/PS1 mice had significant improvement in long-
term memory compared to vehicle-treated AβPP/PS1 mice that was similar to nor-
mal aging C57BL/6J control mice. Furthermore, basal glutamate concentration and 
evoked-glutamate release levels, which were elevated in vehicle-treated AβPP/PS1 
mice, were restored to levels observed in age-matched C57BL/6J mice in AβPP/PS1 
mice receiving prodromal riluzole treatment. Aβ plaque accumulation was not altered 
with riluzole treatment. This study supports that interventions targeting the gluta-
matergic system during the early stages of AD progression have long-term effects on 
disease outcome, and importantly may prevent cognitive decline. Our observations 
provide preclinical support for targeting glutamate neurotransmission in patients at 
risk for developing AD.
K E Y W O R D S
alpha-7 nicotinic acetylcholine receptor (α7nAChR), Alzheimer's disease (AD), amyloid-beta 
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2  |     HASCUP et Al.
1  | INTRODUC TION
Alzheimer's disease (AD) is an age-related neurodegenerative disor-
der resulting in a gradual buildup of Aβ plaques and neurofibrillary 
tangles followed by hippocampal atrophy and progressive demen-
tia (Jack et al., 2013; Mota et al., 2014). Current pharmacotherapy 
options include cholinesterase inhibitors aimed at increasing ace-
tylcholine levels and preventing glutamate-induced excitotoxicity 
through N-methyl-d-aspartate (NMDA) receptor antagonism (Godyń 
et al., 2016). However, these therapies have limited efficacy, are 
symptomatic, and do not decelerate disease progression, which may 
be a consequence of administration at advanced AD stages when 
synapse loss is extensive. To slow or stop AD progression, it may be 
necessary to target neurological components that are altered during 
the prodromal phase of AD. Increasing evidence supports the gluta-
matergic system as a possible early target that meets these criteria 
(Hascup et al., 2019, 2020; Minkeviciene et al., 2008; Paula-Lima 
et al., 2013).
Alterations to glutamate release and clearance may lead to 
the cognitive and functional decline observed in AD (Hascup 
et al., 2019, 2020; Hunsberger et al., 2015; Miller et al., 2008; 
O’Brien et al., 2010). A prevailing hypothesis in AD research sup-
ports persistent, excessive activation of NMDA receptors impedes 
the detection of physiological signals and initiating cognitive im-
pairment (Olney et al., 1997; Parameshwaran et al., 2008; Parsons 
et al., 2007; Talantova et al., 2013; Winblad & Poritis, 1999). Several 
studies have observed hippocampal hyperactivity in mild cogni-
tively impaired patients (Huijbers et al., 2015; Miller et al., 2008; 
O’Brien et al., 2010), particularly those with a familial history of AD 
(Okonkwo et al., 2014) and elevated amyloid-beta (Aβ) deposition 
(Huijbers et al., 2015), that is associated with increased severity of 
cognitive decline (Huijbers et al., 2015; Miller et al., 2008; O’Brien 
et al., 2010). Previous data support that accumulation of soluble 
Aβ isoforms underlie synaptic dysfunction and eventual neuro-
degeneration (Yang et al., 2017). Our laboratory and others have 
demonstrated that soluble Aβ42 elicits glutamate release through 
the alpha-7 nicotinic acetylcholine receptor (α7nAChR) (Hascup 
& Hascup, 2016; Mura et al., 2012; Talantova et al., 2013), which 
may contribute to elevated levels of hippocampal glutamate first 
observed prior to cognitive decline in double transgenic mice ex-
pressing the amyloid precursor protein (Mo/HuAPP695swe) and 
Presenilin 1 (PS1-dE9) genes (AβPP/PS1). Furthermore, we have 
also reported subregion and age specific alterations in hippocampal 
glutamatergic activity in AβPP/PS1. Elevated dentate (DG) and CA1 
evoked glutamate release is observed at 2–4 months of age, while 
elevated basal glutamate in observed in these regions by 6 months 
of age (Hascup et al., 2020). These elevated levels continue to 
12 months of age (Hascup et al., 2018, 2019), when cognitive defi-
cits are more pronounced. These findings indicate early alterations 
to the glutamatergic system evolve throughout disease progression 
as in AβPP/PS1 mice. Furthermore, it supports the hypothesis that 
elevation of synaptic glutamate levels over time may result in excito-
toxicity and eventual hippocampal atrophy observed in AD.
Attenuating glutamatergic tone by targeting glutamate release 
and uptake may provide promising therapeutic interventions for 
early AD. One possible intervention is 2-Amino-6-(trifluoromethoxy) 
benzothiazole (riluzole), which is thought to inhibit presynaptic ex-
citation (Bellingham & Walmsley, 1999; Ireland et al., 2004) and 
glutamate release (Bellingham, 2011; Wang et al., 2004), while also 
restoring transporter expression and activity (Carbone et al., 2012a; 
Fumagalli et al., 2008; Frizzo et al., 2004). Furthermore, riluzole has 
previously shown to attenuate Aβ42-mediated increases in CA1 spike 
frequency and restore the DG excitatory/ inhibitory imbalance re-
sulting in improved cognitive performance (Ren et al., 2015; Yang 
et al., 2020). Based on these previous studies, we hypothesized that 
riluzole treatment has long-term procognitive benefits mediated by 
reducing the glutamatergic tone in amyloidogenic AD mice.
In this study, AβPP/PS1 mice were treated with riluzole 
(2–6 months of age) prior to the onset of cognitive deficits 
(Minkeviciene et al., 2008; Webster et al., 2014). Starting at 
12 months of age, mice underwent Morris water maze (MWM) spa-
tial learning and memory paradigm to assess cognition. This exper-
imental design emphasizes a preventative approach to ameliorating 
the glutamatergic dyshomeostasis and cognitive decline observed at 
12 months of age in this mouse model (Hascup et al., 2018, 2019; 
Minkeviciene et al., 2008; Webster et al., 2014). In vivo hippocampal 
glutamate signaling was assessed using constant potential amper-
ometry followed by immunofluorescence to examine hippocampal 
Aβ plaque burden and expression of several glutamatergic synaptic 
factors. The results presented here support that prodromal riluzole 




Male C57BL/6J (RRID:IMSR_JAX:000664) and AβPP/PS1 
(RRID:MMRRC_034832-JAX) mice were obtained from Jackson 
Laboratory. Protocols for animal use were approved by the 
Laboratory Animal Care and Use Committee at Southern Illinois 
University School of Medicine (Protocol #219-13-012) and the 
study was not pre-registered. Mice were group-housed on a 
12:12 hr light: dark cycle, and food and water were available ad 
libitum. All experiments were conducted during the light phase. A 
timeline of the experimental design is presented in Figure 1. From 
2 to 6 months of age, a randomly assigned cohort of AβPP/PS1 
mice was given riluzole in the drinking water (12.5 mg/kg b.w./
day in 1% sucrose; n = 11). C57BL/6J (n = 14) and the other cohort 
of AβPP/PS1 (n = 12) mice were given 1% sucrose in the drinking 
water as vehicle control. Three mouse cages were pseudo-rand-
omized using the Microsoft Excel randomization function to gen-
erate random decimal numbers between 0 and 1 for each cage and 
treatment. The dosing strategy was based on previously published 
studies using riluzole in vivo (Gourley et al., 2011; Hunsberger 
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et al., 2015; Ishiyama et al., 2004). No exclusion criteria were pre-
determined. All mice underwent cognitive assessment, in vivo 
glutamate recordings, and immunofluorescent analysis except for 
one C57BL/6J vehicle mouse was not used for glutamate meas-
ures because it died due to surgical complications and 3 mice (1 
C57BL/6J vehicle and 2 AβPP/PS1 riluzole) were excluded from 
immunofluorescence because of inadequate sectioning or stain-
ing. Immediately following anesthetized glutamate recordings, 
mice were euthanized with an overdose of isoflurane followed 
by rapid decapitation. A 5 mm tail snip was sent to TransnetYX®, 
Inc to confirm genotypes. All mice were tattooed with unique nu-
merical identifiers to blind researchers throughout experimental 
paradigms.
2.2 | Chemicals
All chemicals were prepared and stored according to manufactur-
er's recommendations unless otherwise noted. l-glutamate oxidase 
(EC 1.4.3.11) was obtained from Cosmo Bio Co. (Cat: YMS-80049) 
and diluted in distilled, deionized water to make a 1 U/µl stock 
solution for storage at 4°C. Sodium phosphate monobasic mono-
hydrate (Cat: BP330-500), sodium phosphate dibasic anhydrous 
(Cat: S375-500), 1,3 phenylenediamine dihydrochloride (mPD; 
Cat: P017225G), sodium chloride (Cat: S271-3), calcium chlo-
ride dehydrate (Cat: BP510-100), sucrose (Cat: 12-550-15), 30% 
hydrogen peroxide (H2O2) in water (Cat: H325-100), and riluzole 
(Cat: 1744-22-5) were obtained from Thermo Fisher Scientific. l-
glutamic acid sodium salt (Cat: G1626), potassium chloride (KCl; 
Cat: P9333), bovine serum albumin (BSA; Cat: A3059), glutaral-
dehyde (Cat: G5882), dopamine hydrochloride (DA; Cat: H8502), 
and l-ascorbic acid (AA; Cat: A7056) were obtained from Sigma-
Aldrich Co. Chicken polyclonal glial fibrillary acidic protein (GFAP) 
primary antibody (RRID:AB_2492333) and Amylo-Glo® RTD™ 
(Cat: TR-300-AG) was obtained from Biosensis. Rabbit polyclonal 
primary antibody α7nAChR was obtained from Alomone Labs 
(RRID:AB_10659339).
2.3 | Morris water maze (MWM) training and 
probe challenge
At approximately 12 months of age, mice underwent cognitive as-
sessment using the MWM spatial learning and memory recall para-
digm. The MWM tests spatial learning and memory by requiring the 
mouse to utilize visual cues to repeatedly swim to a static, submerged 
platform (Bromley-Brits et al., 2011). The MWM paradigm consisted 
of 5 consecutive learning days with three, 90-s trials/day and a 
minimum inter-trial interval of 20 min. After two days without test-
ing, mice are given a single, 60-s probe challenge to test long-term 
memory recall. The ANY-maze video tracking system (Stoelting Co., 
RRID:SCR_014289) was used to record navigational parameters and 
data analysis. The three trials for each training day were averaged 
for each mouse for analysis. Variables extracted from ANY-maze and 
utilized for data analysis include swimming speed, platform cumu-
lative distance, platform corrected integrated path length, percent 
time in quadrant, and annulus 40 entries.
2.4 | Enzyme-based microelectrode arrays
Enzyme-based MEAs were fabricated, assembled, coated, and cali-
brated for in vivo glutamate measurements as previously described 
(Hascup & Hascup, 2015, 2016; Hascup et al., 2016, 2018, 2019). 
One of the R2 MEA Pt sites was coated with l-glutamate oxidase 
solution [containing BSA and glutaraldehyde for enzyme adhesion] 
to enzymatically degrade glutamate to α-ketoglutarate and H2O2, 
the electroactive reporter molecule. The second Pt recording site 
(self-referencing or sentinel site) was coated with a BSA and glutar-
aldehyde solution, which is unable to enzymatically generate H2O2 
from l-glutamate. A potential of +0.7 V versus a Ag/AgCl reference 
electrode was applied to the Pt recording surfaces resulting in oxida-
tion of the H2O2 reporter molecule. The subsequent current gener-
ated from the two-electron transfer was amplified and digitized by 
the Fast Analytical Sensing Technology (FAST) 16mkIII (Quanteon; 
LLC) electrochemistry instrument.
F I G U R E  1   Experimental design. An outline of the experimental design. Riluzole treatment was conducted when mice were 2–6 months 
of age. At 6 months of age, treatment was discontinued and mice were returned to untreated water for the remainder of the study. Animal 
numbers are located underneath each analysis. *One C57BL/6J vehicle treated mouse died due to complications from anesthetized surgical 
procedures. #One C57BL/6J vehicle treated and two AβPP/PS1 mice were excluded from immunofluorescent analysis because of inadequate 
slice preparation and staining procedures. Abbreviations: Morris water maze (MWM)
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2.5 | mPD electropolymerization
After enzyme coating, all Pt recording surfaces were electroplated 
with 5 mM mPD in 0.05 M phosphate-buffered saline (PBS). FAST 
electroplating software applied a triangular wave potential with an 
offset of −0.5 V, peak-to-peak amplitude of 0.25 V, at a frequency of 
0.05 Hz, for 20 min. This created a size exclusion layer that restricts 
the passage of AA, DA, uric acid, and 3,4-dihydroxyphenylacetic 
acid to the Pt recording surface (Hascup et al., 2016).
2.6 | Calibration
Each MEA underwent an in vitro calibration prior to implantation 
to create a standard curve for the conversion of current to gluta-
mate concentration. The Pt recording sites and a glass Ag/AgCl 
reference electrode (Bioanalytical Systems, Inc.) were placed in 
a continuously stirred solution of 40.0 ml of 0.05 M PBS main-
tained at 37°C with a recirculating water bath (Stryker Corp.). 
Final beaker concentrations of 250 µM AA, 10, 20, 30, and 40 µM 
L-glutamate, 2 µM DA, and 8.8 µM H2O2 were used to assess 
MEA performance. Thirty-eight MEAs were used with an aver-
age ± standard error of the mean (SEM) for glutamate sensitiv-
ity of 6.0 ± 0.1 pA/μM (r2 = 0.998 ± 0.001), selectivity ratio of 
391 ± 46 to 1, and limit of detection of 0.2 ± 0.02 μM based on 
a signal-to-noise ratio of 3. A glass micropipette (World Precision 
Instruments, Inc.) was attached to the MEA and used to locally 
apply 70 mM KCl (isotonic; pH 7.4) to the mouse hippocampal sub-
fields (Hascup & Hascup, 2015; Hascup et al., 2016, 2018, 2019). 
The fluid was pressure-ejected using a Picospritzer III (Parker-
Hannafin), with pressure (5–15 psi) adjusted to deliver consistent 
volumes over 1–2 s intervals and monitored with a stereomicro-
scope (Luxo Corp.) fitted with a calibrated reticule.
2.7 | In vivo anesthetized recordings
Beginning one week after MWM, mice were anesthetized using 
1.5%–2.0% isoflurane (Abbott Lab) in a calibrated vaporizer 
(Vaporizer Sales & Service, Inc., Rockmart, GA) and prepared for in 
vivo electrochemical recordings (Hascup et al., 2016, 2018, 2019). 
A Ag/AgCl reference wire was subdurally positioned above the 
right cortex. For each mouse, the MEA/ micropipette assembly 
was lowered into the DG (AP: −2.0, ML: ±1.0, DV: −2.2 mm), CA3 
(AP: −2.0, ML: ±2.0, DV: −2.2 mm), and CA1 (AP: −2.0, ML: ±1.0, 
DV: −1.7 mm), from Bregma (Paxinos & Franklin, 2004) that was 
randomly assigned. Constant voltage amperometry (4 Hz) was 
performed by using a potential of + 0.7 V versus the Ag/AgCl 
reference electrode applied by the FAST16mkIII electrochemical 
instrument (Quanteon LLC). MEAs were allowed to reach a stable 
baseline for 60 min before a 10-s basal glutamate determination 
and pressure ejection studies commenced. The FAST software 
saves amperometric data, time, and pressure ejection events for 
all recording sites. Calibration data, in conjunction with a MATLAB 
(MathWorks) graphic user interface program was used to calculate 
basal glutamate and stimulus-evoked glutamate release and up-
take. Five reproducible signals were evoked in each hippocampal 
subfield and averaged into a representative signal for treatment 
comparisons.
2.8 | Immunodetection, amyloid plaque 
staining, and semiquantification
Immediately following in vivo glutamate measurements, brains 
were fixed in 4% paraformaldehyde for 48 hr and then transferred 
into 30% sucrose in 0.1M phosphate buffer for 24 hr prior to 
sectioning (Hascup et al., 2016, 2018, 2019). Primary antibodies 
were applied to every sixth section (20 µm thickness) from the 
hippocampus at the following concentrations: chicken polyclonal 
GFAP antibody (Biosensis; 1:100) or rabbit polyclonal α7nAChR an-
tibody (Alomone Labs; 1:200). Slides were treated with 10% H2O2 
in 20% methanol for 10 min and then transferred to a 70% ethanol 
solution for 5 min followed by a 2 min wash in PBS. Sections were 
incubated for 10 min in 1× Amylo-Glo® RTD™ and rinsed in 0.9% 
saline for 5 min without shaking followed by rinsing (3 × 2 min) in 
PBS. Sections were permeabilized in PBS with 0.25% TritonX-100 
(PBST) followed by washes (3 × 10 min) in sodium borohydride in 
PBS (1 mg/ml) for antigen retrieval. To control for nonspecific bind-
ing, sections were washed (3 × 10 min) with PBST and incubated in 
10% normal goat serum for 1 hr followed by overnight incubation 
(4°C) with primary antibody. The next day, sections were washed 
(3 × 10 min) in PBST and incubated at room temperature (23°C) for 
1 hr with either AlexaFlour 594 goat anti-chicken (ThermoFisher 
Scientific; 1:1,000; RRID:AB_2534099) or AlexFlour 594 goat anti-
rabbit (ThermoFischer Scientific; 1:1,000, RRID:AB_2534079), re-
spectively. Afterward, sections were washed (3 × 10 min) in PBST 
and coverslipped using Fluoromount-G (SouthernBiotech) either 
with DAPI (α7nAChR) or without DAPI (GFAP/Aβ). To control for 
staining intensity, all sections were allowed to develop overnight 
and imaged the following day. Staining intensity was determined 
using National Institutes of Health Image J Software (v. 1.48; 
RRID:SCR_003070) to measure a grayscale value within the range 
of 0–256, where 0 represents white and 256 represents black. 
Individual templates at two magnifications (10× for GFAP/Aβ; 40× 
for α7nAChR/DAPI) for the DG, CA3, and CA1 were created and 
used on all brains similarly. Images were captured with an Olympus 
1 × 71 microscope equipped with an Olympus-DP73 video camera 
system, and a Dell Optiplex 7020 computer. Measurements were 
performed blinded, and approximately four sections per subregion 
(DG, CA3, and CA1) were averaged to obtain one value per sub-
ject. Amyloid plaques were identified by a dense spherical core 
of intense staining that were often surrounded by a less compact 
spherical halo. Staining density was obtained when background 
staining was subtracted from mean staining intensities on every 
sixth section through the hippocampus.
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2.9 | Data analysis
Sample size was determined based on previous MWM, electrochemi-
cal, and immunofluorescence data using C57BL/6J and AβPP/PS1 
mice. A power calculation indicated a minimum of 10 mice per group 
for MWM and electrochemical recordings and five mice per group 
for immunofluorescent analysis (Hascup et al., 2018) to detect differ-
ences with 95% confidence (a = 0.05) and 0.8 power. Prism (GraphPad 
Software, Inc., RRID:SCR_002798) software was used for statistical 
analyses. To determine if our data plan was appropriate for the col-
lected data, the following assumptions were tested. Significant outli-
ers were identified with a single Grubbs’ test (alpha = 0.05) per group. 
Dependent variables were approximately normally distributed for each 
group of the independent variable as determined with the Anderson-
Darling test as well as visual quantile-quantile plots. A Brown-Forsythe 
test indicated homogeneity of variances was reasonably met allowing 
us to proceed with our statistical tests. MWM trial days were analyzed 
with a two-way ANOVA while the MWM probe challenge, glutamate 
recordings, and immunofluorescent semiquantification was analyzed 
with a one-way ANOVA. When the ANOVA indicated a statistically 
significant main effect, a Dunnett's post hoc analysis was used to de-
termine treatment differences against the AβPP/PS1 vehicle-treated 
cohort. A two-tailed Student's t test was used to compare amyloid 
plaques in both AβPP/PS1 cohorts. Hippocampal subregions were 
analyzed independently for glutamate recordings and immunofluo-
rescent semiquantification. Data are represented as mean ± SEM and 
statistical significance was defined as p < .05.
3  | RESULTS
3.1 | Riluzole mouse weights
Mice were weighed one week prior to starting treatment and then 
weekly until treatment completion and again during the MWM. 
Mice gained weight similarly (Table 1) and weight differences were 
not observed between treatment groups throughout the study 
(F2,34 = 0.28, p = .75) supporting that riluzole treatment did not 
cause nausea-like response.
3.2 | Riluzole cognitive assessment
Six months post riluzole treatment, all mice underwent MWM test-
ing. No differences in swim speed across treatment groups was 
observed on any training day (Figure 2a) indicating similar motor 
capabilities. A significant main effect over training days of the cor-
rected integrated path length (CIPL) to the platform (Figure 2b; 
F4,136 = 17.20, p < .0001) and cumulative distance from the plat-
form (Figure 2c; F4,136 = 16.46, p < .0001) was observed indicating 
all treatment groups successfully learned the location of the hidden 
escape platform. Additionally, a main effect of treatment groups was 
also observed for the CIPL to the platform (F2,34 = 10.99, p = .0002) 
and cumulative distance from the platform (F2,34 = 10.61; p = .0003). 
Post hoc analysis indicated that AβPP/PS1 vehicle mice were slower 
to learn the location of the hidden escape platform compared to both 
C57BL/6J vehicle and AβPP/PS1 riluzole mice over the first 3 training 
days. No differences were observed over subsequent training days. 
Representative tracking plots of the 60-s probe challenge are shown 
in Figure 2d. During the probe challenge, swim speed was consistent 
across treatment groups (Figure 2e) indicating differences in mem-
ory retention was not a result of motor performance. Analysis of the 
percentage of time spent in each quadrant indicate a main effect of 
quadrant occupancy in C57BL/6J vehicle (F3,52 = 15.43, p < .0001), 
AβPP/PS1 riluzole (F3,40 = 13.42, p < .0001), and AβPP/PS1 vehicle 
(F3,44 = 17.39, p < .0001). But a post hoc analysis revealed that AβPP/
PS1 vehicle mice were the only treatment group to not selectively 
search the target quadrant for the former location of the hidden 
escape platform during the probe challenge (Figure 2f). A main ef-
fect of the number of annulus 40 entries (F2,34 = 3.36, p = .04) was 
observed. Post hoc analysis indicated that AβPP/PS1 vehicle mice 
entered the annulus 40 fewer times compared to C57BL/6J vehicle 
mice with a trend to improved performance after riluzole treatment 
(Figure 2g). These data support that 12-month-old AβPP/PS1 vehi-
cle-treated mice have impaired cognition compared to age-matched 
C57BL/6J mice and that four months of riluzole treatment had long-
lasting effects in its ability to rescue learning and memory deficits in 
AβPP/PS1 mice; similar to normal aging C57BL/6J mice.
3.3 | Riluzole glutamate measures
Representative traces of stimulus-evoked glutamate release are 
shown in Figure 3a. A main effect on treatment group for basal 
glutamate (Figure 3b) was observed in the DG (F2,33 = 15.65, 
p < .0001), CA3 (F2,33 = 9.03, p = .0007), and CA1 (F2,33 = 13.97, 
p < .0001). A post hoc analysis revealed that AβPP/PS1 vehicle hip-
pocampal basal glutamate was significantly elevated compared to 
C57BL/6J vehicle and AβPP/PS1 riluzole mice. Similar volumes of 
70 mM KCl (Figure 3c) were used to elicit glutamate release in the 
Treatment group
Mouse weight percent change (mean ± SEM)
3 months 4 months 5 months 6 months 12 months
C57BL/6J Vehicle 8.5 ± 0.7 14.0 ± 0.9 18.13 ± 1.5 17.9 ± 2.7 36.2 ± 1.9
AβPP/PS1 Vehicle 7.0 ± 1.1 12.2 ± 2.8 16.3 ± 3.3 16.6 ± 3.4 39.7 ± 3.5
AβPP/PS1 Riluzole 8.2 ± 0.7 13.2 ± 1.0 18.4 ± 1.8 21.7 ± 1.8 39.9 ± 2.6
TA B L E  1   Average percent change of 
mouse weight during the 4 months of 
riluzole treatment (3–6 months of age) and 
at the time of testing (12 months of age)
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DG (F2,33 = 0.4905, p = .61), CA3 (F2,33 = 2.43, p = .10), and CA1 
(F2,33 = 0.20, p = .82). A main effect of stimulus-evoked glutamate 
release (Figure 3d) was observed in the DG (F2,33 = 5.77, p = .0071), 
CA3 (F2,33 = 8.07, p = .0014) and CA1 (F2,33 = 13.87, p < .0001). A 
post hoc analysis indicated that hippocampal glutamate release was 
increased in AβPP/PS1 vehicle-treated compared to both C57BL/6J 
vehicle- and AβPP/PS1 riluzole-treated mice. A main effect on the 
uptake rate of stimulus-evoked glutamate release (Figure 3e) was 
observed in the CA3 (F2,33 = 7.16, p = .0026) and CA1 (F2,31 = 5.05, 
F I G U R E  2   MWM training and probe challenge. Mice were 
trained to locate a hidden escape platform over five consecutive 
days. Each training day consisted of three trials that were averaged 
into a single data point for each treatment group to analyze 
swimming speed (a) CIPL (b) and cumulative distance (c). CIPL 
adjusts for average swim speed and corrects the difference in 
distance between different start positions and distance to the 
platform. Representative track plots of the 60 s probe challenge are 
shown for each treatment group (d). No differences in swimming 
speed were observed during the probe challenge (e) indicating 
motor performance does not account for differences in cognitive 
measurements. C57BL/6J vehicle and AβPP/PS1 riluzole mice, 
but not AβPP/PS1 vehicle mice, selectively searched the target 
quadrant compared to the other quadrants for the former location 
of the hidden escape platform (f). AβPP/PS1 vehicle mice entered 
the annulus 40 (immediate area surrounding the platform) fewer 
times compared to C57BL/6J vehicle and AβPP/PS1 riluzole 
mice (g). N = number of mice. A–c: two-way ANOVA, Dunnett's 
post hoc; (e–g): one-way ANOVA, Dunnett's post hoc; *p < .05, 
**p < .01, AβPP/PS1 vehicle (n = 12) versus C57BL/6J vehicle mice 
(n = 14); §§p < .01, §§§p < .001 AβPP/PS1 vehicle versus AβPP/PS1 
riluzole mice (n = 11)
F I G U R E  3   Representative glutamate traces and glutamate 
measures. (a) Representative traces of basal glutamate and 
stimulus-evoked glutamate release from 70 mM KCl stimulation. 
Treatment groups are placed into columns and hippocampal 
subfields are shown in rows. The inset trace at the top of each 
panel displays the reproducibility of glutamate release and 
clearance, while the single response is a magnified view of the 
first inset signal to give a clearer presentation of dynamics of 
glutamatergic signaling. Concentration and time axes are consistent 
in all panels for comparisons. (b) Basal glutamate was determined 
prior to local application of 70 mM KCl in each hippocampal 
subfield. (c) The volume of stimulus ejected was consistent across 
treatment groups for direct comparisons of evoked glutamate 
release. (d) The average glutamate release was determined by 
subtracting the peak amplitude from the basal measure obtained 
prior to each ejection of the stimulus. (e) Glutamate uptake rate was 
calculated by multiplying the peak response (µM) by logarithmic 
slope (k−1) of glutamate decay versus time (s
−1) as estimated by the 
use of regression analysis (R2 ≥ 0.9). N = number of mice. A one-way 
ANOVA with Dunnett's post hoc was used in each hippocampal 
subfield. *p < .05; **p < .01, ***p < .001, ****p < .0001 AβPP/PS1 
vehicle (11–12) versus C57BL/6J vehicle (n = 12–13) mice; §p < .05, 
§§p < .01, §§§p < .001, §§§§p < .0001 AβPP/PS1 vehicle versus AβPP/
PS1 riluzole (n = 11) mice
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p = .0126), but not the DG (F2,33 = 0.15, p = .86). A post hoc analysis 
indicates AβPP/PS1 vehicle mice have a faster glutamate uptake rate 
compared to both C57BL/6J vehicle and AβPP/PS1 riluzole-treated 
mice in the CA3 and CA1. These data support that 12-month-old 
AβPP/PS1 mice have elevated basal glutamate and evoked glutamate 
release compared to age-matched C57BL/6J mice and that four 
months of riluzole treatment resulted in attenuated hippocampal 
glutamatergic tone in AβPP/PS1 mice; similar to levels observed in 
cognitively normal C57BL/6J mice.
3.4 | Immunofluorescence
3.4.1 | α7nAChR
We previously reported that soluble Aβ42 interacts with presynaptic 
α7nAChRs to stimulate glutamate release in the DG, CA1, and CA3 
hippocampal subregions (Hascup & Hascup, 2016). To determine if 
differences in stimulus-evoked glutamate release were a result of 
altered α7nAChR density, we used immunofluorescence to measure 
changes in α7nAChR. The specificity of the α7nAChR primary anti-
body has been previously demonstrated in α7nAChR knockout mice 
(Nishio et al., 2017) and a negative control confirming it's specific-
ity in mouse hippocampal tissue is shown in Supplemental Figure 1. 
Representative images from the CA1 of C57BL/6J vehicle-, AβPP/PS1 
vehicle-, and AβPP/PS1 riluzole-treated mice are shown (Figure 4a-I). 
We observed no significant differences in between treatment groups 
for each hippocampal subregion (DG: F2,31 = 1.263, p = .1992; CA1: 
F2,31 = 4.014, p = .1068; CA3: F2,31 = 3.465, p = .0811). Changes 
in glutamate dynamics across treatment groups was not a result of 
α7nAChR expression differences, thereby negating potential differ-
ences due to Aβ42-mediated glutamate release at these receptors.
3.4.2 | GFAP and Aβ plaques staining
Immunofluorescence was used to measure changes in GFAP, while 
plaque pathology was determined using Amylo-Glo staining reagent. 
Representative images of C57BL/6J vehicle-, AβPP/PS1 vehicle-, 
and AβPP/PS1 riluzole-treated mice from the DG (Figure 5a–c; Top) 
and the CA1/ CA3 (Figure 5d–f; Bottom). Merged images highlight 
astrogliotic responses surrounding amyloid plaques in both cohorts 
of AβPP/PS1 mice. GFAP average mean densities for each hippocam-
pal subfield are presented in Figure 5g. No differences in the av-
erage mean density of GFAP for each hippocampal subregion were 
observed, indicating differences in glutamate uptake rate are not 
attributed to astrocyte density (DG: F2,30 = 1.272, p = .2951; CA1: 
F2,30 = 0.1813, p = .8351; CA3: F2,30 = 0.4370, p = .65). The number 
of hippocampal amyloid plaques for both cohorts of AβPP/PS1 mice 
are shown in Figure 5h. Riluzole treatment had no effect on amyloid 
accumulation in the DG (t19 = 0.2301, p = .82), CA3 (t19 = 0.4791, 
p = .64), nor CA1 (t19 = 0.2926, p = .77).
4  | DISCUSSION
Riluzole is a Food and Drug Administration approved drug for the 
treatment of ALS and is undergoing a Phase II clinical trial for the 
treatment of mild AD (Clinical Trial #NCT01703117). Riluzole is 
known to target the glutamatergic system to achieve enhanced glu-
tamate uptake and attenuate glutamate release. Elevated glutamate 
uptake may be due to improved function/activity of Na+-K+-ATPase 
(Deng et al., 2009), glutamate transporter-1 (Fumagalli et al., 2008), 
and the glutamate/glutamine (Glu/Gln) cycle (Deng et al., 2009). 
Immunofluorescent staining for Glt-1 indicated no differences 
across treatment groups (data not shown). This may indicate riluzole-
mediated changes to the Glu/Gln cycle may be several-fold. First, 
F I G U R E  4   Hippocampal α7nAChR expression. (a) 
Representative 40× images (scale bar = 20 µM) of DAPI (blue) 
and α7nAChR (red) expression in the DG (a–c), CA3 (d–f), and CA1 
(g–i) for the three treatment groups separated into columns. The 
average mean α7nAChR staining density is shown in (j). A one-way 
ANOVA with Dunnett's post hoc was used in each hippocampal 
subfield. N = number of mice; C57BL/6J vehicle (n = 13), AβPP/PS1 
vehicle (n = 12); AβPP/PS1 riluzole (n = 9) mice
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evidence supports enhanced astrocytic glutamine synthetase with 
riluzole treatment (Deng et al., 2009), which breaks down glutamate 
to glutamine and may help to stimulate glutamate uptake. Glutamine 
shuttling from astrocytes to neurons is also increased with riluzole 
treatment (Chowdhury et al., 2008), however, riluzole also potently 
inhibits the high-affinity glutamine transport system (Gln/ 2-(methyl-
amino) isobutyrate) responsible for transporting glutamine into neu-
rons (Erickson, 2017), effectively decreasing the glutamine pool in 
neurons available to produce glutamate. This is further confounded 
by an increase in glutamate metabolism with more glutamate en-
tering into the tricarboxylic acid cycle (Chowdhury et al., 2008). 
Together, these actions have a combined effect of increasing gluta-
mate clearance and inhibiting glutamate release, yet it is unclear how 
long these metabolic actions persist after cessation of drug treat-
ment or if there is a long-term effect on cognition.
We have previously shown that tight regulation of hippocampal 
glutamatergic signaling is involved in successful aging in a mouse 
model of longevity and improved healthspan (Hascup et al., 2015, 
2016), evoked glutamate release is increased in the CA1 of young 
(2–4 months old) AβPP/PS1 mice without detectable changes in 
basal glutamate levels (Hascup et al., 2020), and soluble Aβ42, which 
is one of the earliest detectable biomarkers of AD (Jack et al., 2013), 
elicits glutamate release (Hascup & Hascup, 2016). More recently, we 
determined that both evoked glutamate release and basal glutamate 
levels were elevated throughout the hippocampus by 12 months of 
age (Hascup et al., 2019). These data support that subregion specific 
changes to hippocampal glutamate neurotransmission is altered as 
a function of AD progression. Therefore, targeting the glutamater-
gic system, specifically by decreasing glutamate release, increasing 
glutamate clearance, or both, during the prodromal phase may alter 
disease outcome. Recent studies have shown that riluzole is effec-
tive at treating early life stress-induced cognitive decline and syn-
aptic impairments (Lesuis et al., 2019), protects against age-related 
synaptic alterations related to memory loss (Pereira et al., 2014), 
and is effective at treating depression in pre-clinical models (Banasr 
et al., 2010). Furthermore, chronic riluzole treatment reverses gene 
expression changes observed in microglia, astrocytes, and neurons, 
and improves memory and pathology in a model of early-onset AD 
(Okamoto et al., 2018). Previous studies have also shown the res-
toration of glutamatergic neurotransmission with chronic riluzole 
treatment in a tau model of AD (Hunsberger et al., 2015). As such, 
riluzole is an ideal candidate for early therapeutic intervention for 
AD. However, it is unknown if riluzole has long-term glutamate mod-
ulating or procognitive effects. Therefore, we aimed to determine 
the long-term therapeutic benefits of prodromal riluzole treatment 
in the AβPP/PS1 mouse model of progressive amyloidosis.
Due to the general lack of success of AD treatments that begin 
after noticeable onset of cognitive decline our treatment strategy 
was aimed at early intervention through restoration of glutamatergic 
signaling prior to cognitive decline. We used riluzole as a prodomal 
treatment that has the potential alter AD outcome if administered 
at the earliest signs of altered glutamatergic neurotransmission. The 
AβPP/PS1 mouse model of AD that we use in the proposal are cogni-
tively normal, lack AD neuropathology, but have elevated glutamate 
release at 2–4 months of age, begin showing cognitive decline and 
Aβ plaque accumulation at approximately 6–8 months of age, and 
have advanced AD neuropathology and are cognitively impaired at 
10–12 months. The early four month Riluzole treatment (2–6 months 
of age) allowed us to complete administration targeting these early 
changes in glutamatergic neurotransmission prior to measurable 
cognitive decline in this AD model. The interval between treatment 
cessation and initiation of cognitive testing allowed us to take ad-
vantage of cognitive differences observed at 12 months of age while 
also examining potential long-term benefits of early intervention 
aimed at restoring glutamatergic neurotransmission, thereby delay-
ing and/or preventing AD-related cognitive decline.
Consistent with our previous work, glutamatergic dysfunc-
tion and decreased cognition were observed in AβPP/PS1 vehi-
cle-treated mice at 12 months of age (Hascup et al., 2018, 2019). 
Here, we built on that knowledge and show that both basal gluta-
mate and evoked glutamate release are elevated at this time point, 
supporting alterations to the glutamatergic neurotransmission are 
in flux as a result of disease progression. Prodromal riluzole treat-
ment from (2–6 months of age), followed by six months without 
F I G U R E  5   Hippocampal GFAP/Aβ expression. (a) 
Representative 10× images (Scale bar = 100 µM) of GFAP (red) and 
Aβ plaque (blue) expression, with 40× insets (scale bar = 20 µm), in 
the DG (a–c) and CA1/CA3 (d–f) hippocampal subregions for the 
three treatment groups (columns). Subregion-specific changes in 
GFAP expression (g) was compared using a one-way ANOVA with 
Dunnett's post hoc, while a t test was used for comparing plaque 
accumulation between riluzole and vehicle treated AβPP/PS1 
groups (h). N = number of mice
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treatment, rescued basal glutamate and evoked glutamate release 
in 12-month-old AβPP/PS1 mice to levels consistent with those 
observed in vehicle-treated normal aging C57BL/6 control mice. 
AβPP/PS1 riluzole-treated mice also had improved spatial learn-
ing and memory performance compared to vehicle-treated gen-
otype-matched mice, indicating that riluzole may have long-term 
procognitive benefits.
Since we did not observe long-term effects on glutamate neu-
rotransmission or cognition with LY379268 administration under 
a similar treatment regimen (Hascup et al., 2019), it is unlikely that 
these effects were mediated through metabotropic glutamate re-
ceptor 2/3. Current literature would support a multi-part mechanism 
to inhibit presynaptic glutamate release and prevent overstimula-
tion of the glutamatergic synapse (Bellingham & Walmsley, 1999; 
Bellingham, 2011; Ireland et al., 2004; Wang et al. 2004). Based on 
our previous characterizations of glutamatergic neurotransmission 
during the prodromal period in AβPP/PS1 mice (Hascup et al., 2019; 
Hascup & Hascup, 2015), inhibition of neuronal excitation during 
this time should be the most advantageous in preventing subse-
quent neuronal damage and cognitive decline. However, Hunsberger 
et al. (2015) demonstrated that riluzole may also be efficacious 
later in disease progression as it was shown to effectively mediate 
elevated glutamate neurotransmission in a tau model of AD. Since 
hyperphosphorylated tau is typically observed later in disease pro-
gression, the neuropathological profile for each patient may need to 
be considered for optimal treatment efficacy.
Previous data support a decrease in GFAP immunoreactivity with 
riluzole treatment (Carbone et al., 2012b; Fumagalli et al., 2006). In 
this study, we observed astrocyte clustering around amyloid plaques 
which has been previously noted (Carbone et al., 2012b; Hascup 
et al., 2018), but no differences in GFAP mean density in any of the 
hippocampal subregions with riluzole treatment. The inability of ri-
luzole to reduce GFAP immunoreactivity in this model could possi-
bly be due to the retention of plaque load regardless of treatment. 
Continuation of plaque accumulation throughout disease progres-
sion results in a chronic inflammatory response (Findley et al., 2019; 
Hascup et al., 2018; Olabarria et al., 2010) that riluzole treatment 
does not attenuate. Further, we cannot rule out a role of soluble Aβ 
in chronic inflammation. But, the reported changes in glutamater-
gic neurotransmission across treatment groups was not a result of 
α7nAChR expression differences that could have affected soluble 
Aβ42-mediated stimulation.
Overall, the results of this study support the use of riluzole as an 
early therapeutic intervention strategy to ameliorate cognitive de-
cline and restore glutamatergic tone. Additional studies are ongoing 
to elucidate riluzole's mechanism of action in this AD model that in-
cludes presynaptic and postsynaptic modifications of glutamatergic 
signaling as well as any sex differences in glutamate-related pathol-
ogy and response to riluzole treatment.
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